In contrast to PD-1-negative cells, which are the limiting factor in the tumor specificity of cells produced from bulk CD8+ TILs, PD-1-positive T cell subsets have been shown to have advantages for adoptive T-cell treatment [111]. The gene discussed is CD8A; the disease is neoplasm.